400 results on '"Gassull, M. A."'
Search Results
2. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases:an International Organization for Study of Inflammatory Bowel Diseases consensus
3. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
4. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
5. European evidence-based Consensus on the management of ulcerative colitis: Current management
6. Caracterización de biomarcadores en la recurrencia postquirúrgica de la enfermedad de Crohn : valor predictivo y/o implicación patogénica de los mismos
7. Estudi de l'efecte del tractament amb Adalimumab sobre la microbiota associada a la mucosa intestinal en pacients amb malaltia de Crohn
8. Conocimiento de la fisiopatología de la Enfermedad Inflamatoria Intestinal a partir del estudio de su incidencia (Departamento de Salud 6 de Valencia)
9. CARD4/NOD1 is not involved in inflammatory bowel disease. (Inflammatory Bowel Disease)
10. Use of anti-tumour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001–2003
11. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice
12. Clinical outcome of newly diagnosed Crohnʼs disease: a comparative, retrospective study before and after infliximab availability
13. The effect of olive oil on inflammatory bowel disease.
14. Plasma and Mucosal Fatty Acid Pattern in Colectomized Ulcerative Colitis Patients
15. TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort
16. Reduced liver injury in the interleukin-6 knockout mice by chronic carbon tetrachloride administration
17. Efficacy and safety of short-term adalimumab treatment in patients with active Crohnʼs disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial
18. Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease
19. Introduction: new approaches to the detection and management of inflammatory bowel disease: from genetic testing to treatment strategies
20. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations
21. Is oral ciclosporin necessary to switch from i.v. to thiopurines?
22. Duodéno-jéjunite ulcéreuse d’étiologie vasculaire
23. Clinical evolution of luminal and perianal Crohnʼs disease after inducing remission with infliximab: how long should patients be treated?
24. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study
25. the role of nutrition in the treatment of inflammatory bowel disease
26. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohnʼs disease
27. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis
28. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohnʼs disease: results of a double blind randomised multicentre European trial
29. Genetic analyses of chromosome 12 loci in Crohnʼs disease
30. Antineutrophil antibodies associated with ulcerative colitis interact with the antigen(s) during the process of apoptosis
31. Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E2 synthesis
32. Occlusion of the superior mesenteric artery in a patient with Polycythemia vera: Resolution with percutaneous transluminal angioplasty
33. Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis
34. Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis
35. Changes of the mucosal n3 and n6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence
36. Metabolic Effects Of Bran
37. Glucose Absorption And Diabetes
38. 111In-Oxine-labelled autologous leucocytes in inflammatory bowel disease: New scintigraphic activity index
39. A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects: A dose-response, double-blind, placebo-controlled, randomized pilot trial
40. A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects: A dose-response, double-blind, placebo-controlled, randomized pilot trial
41. Mesalazine and the prevention of colorectal cancer in inflammatory bowel disease
42. RIP2 polymorphisms in inflammatory bowel diseases
43. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: Current management
44. Efecto de la administración de triglicéridos de cadena media y ácidos grasos poliinsaturados ω-3 en la prevención y tratamiento de la fibrosis hepática en un modelo murino (ratones C57BL/6) de esteatohepatitis no alcohólica
45. Influencia de los ácidos grasos dietéticos y del ambiente en el desarrollo de colitis espontánea en ratones IL-10(-/ -)
46. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
47. TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort
48. Efectes de l'oli de peix i l'oli d'oliva en el desenvolupament del càncer colorectal
49. La Interleucina-6 secretada per les cèl·lules de Kupffer és la responsable de la iniciació del procés de regeneració hepàtica post-hepatectomia parcial en un model animal experimental
50. RIP2 polymorphisms in inflammatory bowel diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.